VB Spine has funded the next phase of scoliosis diagnostic research led by Alain Moreau, PhD, according to a June 3 news release.
Dr. Moreau’s research is looking into whether biomarkers present in patient blood could help predict spinal deformity progression. Initial studies in 2006 demonstrated proof of concept, and further per-reviewed research has validated the underlying science.
VB Spine’s funds will support a new phase that focuses on further clinical validation, FDA submission and commercialization of the predictive test.
“We are on the threshold of what could become the first truly predictive test to identify children at risk of developing severe scoliosis, opening the door to earlier interventions,” Dr. Moreau said in the release. “I am excited about this strategic alliance with VB Spine. It reflects a bold and forward-looking vision and long-standing commitment to bringing transformative innovations to patients.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
